Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Author's Avatar
Apr 26, 2023

Posters will feature preliminary Phase 1b combination data for potential best-in-class ERK1/2 inhibitor ERAS-007 with encorafenib and cetuximab or with palbociclib in patients with GI malignancies